Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Bought by Howe & Rusling Inc.

Howe & Rusling Inc. lifted its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 9.5% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 506 shares of the biopharmaceutical company’s stock after acquiring an additional 44 shares during the quarter. Howe & Rusling Inc.’s holdings in Regeneron Pharmaceuticals were worth $360,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of the stock. Intact Investment Management Inc. acquired a new position in shares of Regeneron Pharmaceuticals in the 4th quarter valued at $356,000. Principal Financial Group Inc. boosted its holdings in shares of Regeneron Pharmaceuticals by 1.7% in the third quarter. Principal Financial Group Inc. now owns 173,092 shares of the biopharmaceutical company’s stock worth $181,961,000 after buying an additional 2,828 shares during the period. Golden State Equity Partners boosted its holdings in shares of Regeneron Pharmaceuticals by 1,479.1% in the fourth quarter. Golden State Equity Partners now owns 1,358 shares of the biopharmaceutical company’s stock worth $967,000 after buying an additional 1,272 shares during the period. Fagan Associates Inc. increased its position in shares of Regeneron Pharmaceuticals by 42.2% in the fourth quarter. Fagan Associates Inc. now owns 12,923 shares of the biopharmaceutical company’s stock worth $9,205,000 after acquiring an additional 3,832 shares in the last quarter. Finally, ABC Arbitrage SA acquired a new stake in shares of Regeneron Pharmaceuticals during the fourth quarter valued at approximately $1,510,000. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Trading Down 0.7 %

Regeneron Pharmaceuticals stock opened at $635.83 on Friday. The business’s 50-day simple moving average is $684.76 and its 200-day simple moving average is $803.87. Regeneron Pharmaceuticals, Inc. has a 52 week low of $629.02 and a 52 week high of $1,211.20. The firm has a market capitalization of $69.51 billion, a PE ratio of 16.61, a PEG ratio of 2.34 and a beta of 0.27. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.95 and a current ratio of 4.73.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 EPS for the quarter, topping analysts’ consensus estimates of $11.21 by $0.86. The company had revenue of $3.79 billion during the quarter, compared to analyst estimates of $3.76 billion. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The company’s quarterly revenue was up 10.3% compared to the same quarter last year. During the same period in the previous year, the company earned $11.86 earnings per share. Equities research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Thursday, March 20th. Stockholders of record on Thursday, February 20th were issued a dividend of $0.88 per share. The ex-dividend date was Thursday, February 20th. This represents a $3.52 annualized dividend and a dividend yield of 0.55%. Regeneron Pharmaceuticals’s payout ratio is 2.30%.

Analyst Ratings Changes

A number of equities analysts recently commented on REGN shares. Canaccord Genuity Group lowered shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, December 17th. Truist Financial lowered their price target on Regeneron Pharmaceuticals from $1,126.00 to $1,004.00 and set a “buy” rating on the stock in a report on Wednesday, January 8th. Citigroup dropped their price target on Regeneron Pharmaceuticals from $795.00 to $750.00 and set a “neutral” rating on the stock in a research report on Tuesday, January 28th. UBS Group lowered Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and decreased their price objective for the stock from $1,130.00 to $738.00 in a research report on Thursday, January 16th. Finally, Wells Fargo & Company dropped their target price on Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an “overweight” rating on the stock in a report on Friday, January 10th. One analyst has rated the stock with a sell rating, six have assigned a hold rating, seventeen have given a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $973.13.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.